Bcl-2 and N-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines

被引:18
作者
Jasty, R
van Golen, C
Lin, HJ
Solomon, G
Heidelberger, K
Polverini, P
Opipari, A
Feldman, E
Castle, VP
机构
[1] Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA
[4] Univ Michigan, Sch Med, Dept Dent, Ann Arbor, MI USA
[5] Univ Michigan, Sch Med, Dept Obstet & Gynecol, Ann Arbor, MI USA
[6] Med Coll Ohio, Dept Pediat, Toledo, OH 43699 USA
来源
NEOPLASIA | 2001年 / 3卷 / 04期
关键词
neuroblastoma; apoptosis; angiogenesis; tumorigenicity; N-Myc;
D O I
10.1038/sj.neo.7900171
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The bcl-2 and c-myc oncogenes cooperate to transform multiple cell types. In the pediatric malignancy NB2, Bcl-2 is highly expressed. In tumors with a poor prognosis, N-Myc, a protein homologous to c-Myc, is overexpressed as a result of gene amplification. The present study was designed to determine whether Bcl-2 cooperates with N-Myc to bestow a tumorigenic phenotype to neuroblastoma (NB) cells. NS cell lines that at baseline express neither Bcl-2 nor N-Myc were stably transfected to express these gene products. In this model, we found Bcl-2 rescues N-Myc-expressing cells from apoptosis induced by serum withdrawal. Coexpression of Bcl-2 and N-Myc supports growth in low serum conditions and anchorage-independent growth in soft agar. Similarly, in vivo tumorigenic and angiogenic activity was dependent on coexpression. Our data further suggests that the mechanism underlying these changes involves the receptor for insulin growth factor type I (IGF-IR).
引用
收藏
页码:304 / 313
页数:10
相关论文
共 46 条
[1]   APOPTOTIC CELL-DEATH INDUCED BY C-MYC IS INHIBITED BY BCL-2 [J].
BISSONNETTE, RP ;
ECHEVERRI, F ;
MAHBOUBI, A ;
GREEN, DR .
NATURE, 1992, 359 (6395) :552-554
[2]   AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE [J].
BRODEUR, GM ;
SEEGER, RC ;
SCHWAB, M ;
VARMUS, HE ;
BISHOP, JM .
SCIENCE, 1984, 224 (4653) :1121-1124
[3]  
Brodeur GM, 1993, PRINCIPLES PRACTICE, P739
[4]  
BRONDYK WH, 1991, ONCOGENE, V6, P1269
[5]   ANTISENSE-MEDIATED REDUCTION IN THROMBOSPONDIN REVERSES THE MALIGNANT PHENOTYPE OF A HUMAN SQUAMOUS CARCINOMA [J].
CASTLE, V ;
VARANI, J ;
FLIGIEL, S ;
PROCHOWNIK, EV ;
DIXIT, V .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) :1883-1888
[6]  
CASTLE VP, 1993, AM J PATHOL, V143, P1543
[7]  
Chambéry D, 1999, CANCER RES, V59, P2898
[8]   The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation [J].
Cole, MD ;
McMahon, SB .
ONCOGENE, 1999, 18 (19) :2916-2924
[9]  
CORY S, 1999, CANCER RES, V59, P1685
[10]  
COZZUTTO C, 1991, ARCH PATHOL LAB MED, V115, P68